Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study-Reference-Cited by-同舟云学术

Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study

Published:2013-12-15 Issue:11 Volume:231 Page:2299-2310
ISSN:0033-3158
Container-title:Psychopharmacology
language:en
Short-container-title:Psychopharmacology

Author:

Risinger Robert,Bhagwagar Zubin,Luo Feng,Cahir Matthew,Miler Laura,Mendonza Anisha E.,Meyer Jeffrey H.,Zheng Ming,Hayes Wendy

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s00213-013-3391-3.pdf

Reference42 articles.

1. Aluisio L, Lord B, Barbier AJ, Fraser IC, Wilson SJ, Boggs J, Dvorak LK, Letavic MA, Maryanoff BE, Carruthers NI, Bonaventure P, Lovenberg TW (2008) In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor. Eur J Pharmacol 587:141–146

2. DeLorenzo C, Lichenstein S, Schaefer K, Dunn J, Marshall R, Organisak L, Kharidia J, Robertson B, Mann JJ, Parsey RV (2011) SEP-225289 serotonin and dopamine transporter occupancy: a PET study. J Nucl Med 52:1150–1155

3. Fischman AJ, Bonab AA, Babich JW, Livni E, Alpert NM, Meltzer PC, Madras BK (2001) [11C, 127I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse 39:332–342

4. Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S (2001) Positron emission tomography quantification of [11C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 21:1342–1353

5. Golembiowska K, Kowalska M, Bymaster FP (2012) Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. Synapse 66:434–444

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder—A Narrative Review;Pharmaceuticals;2023-03-08

2. D-578, an orally active triple monoamine reuptake inhibitor, displays antidepressant and anti-PTSD like effects in rats;European Journal of Pharmacology;2019-11

3. Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges;Journal of Medicinal Chemistry;2017-07-21

4. Enabling Synthesis of Triple Reuptake Inhibitor (+)-BMS-820836, a Potential Therapeutic Agent for the Treatment of Depression;Organic Process Research & Development;2016-01-04

5. Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?;Future Medicinal Chemistry;2015-11